Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN 3.5%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.
Total parenteral nutrition (TPN) in patients who cannot tolerate adequate oral or enteral nutrition,Peripheral parenteral nutrition (PPN) when central venous access is not available
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral/enteral nutrition is impossible or insufficient
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
The plasma half-life of individual amino acids varies; for total amino acid mixture, the terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic and renal function, reflecting rapid uptake into tissues and metabolism. This half-life is clinically relevant for continuous infusion scheduling.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the citric acid cycle; insulin secretion increases in response to dextrose.
Amino acids are metabolized primarily in the liver via deamination, transamination, and urea cycle; some metabolism occurs in peripheral tissues.
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Amino acids are primarily eliminated via hepatic metabolism (deamination, transamination) and renal excretion. The renal excretion accounts for approximately 5-10% of the administered dose as unchanged amino acids; the majority is metabolized, and nitrogen is excreted as urea (80-90% of nitrogen) via urine, with minor fecal losses (<5%).
Not applicable; amino acids and dextrose do not bind to plasma proteins.
Amino acids have minimal protein binding (less than 10%), primarily to albumin, but binding is negligible for pharmacokinetic purposes.
Not applicable; distributes throughout total body water.
Volume of distribution for amino acids is approximately 0.2-0.4 L/kg, reflecting distribution primarily into extracellular fluid and lean tissue compartments. This low Vd indicates limited extravascular distribution.
Intravenous: 100% bioavailable.
Intravenous: 100% bioavailability. Not applicable to other routes; oral administration is not indicated due to first-pass metabolism and variable absorption.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50% or monitor BUN and creatinine; GFR <10 m L/min: avoid unless on dialysis; adjust based on nitrogen balance and fluid status.
For GFR 30-59 m L/min: reduce dose by 50% and monitor serum BUN. For GFR 15-29 m L/min: reduce dose by 75%. For GFR <15 m L/min: avoid use unless on renal replacement therapy; if used, adjust based on amino acid losses during dialysis.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor ammonia; Child-Pugh C: avoid use due to risk of encephalopathy from amino acid load.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% and monitor ammonia levels. Child-Pugh Class C: avoid use or use with caution, reduce dose by 75% and monitor for hepatic encephalopathy.
Neonates and infants: initial 0.5-1 g amino acids/kg/day, increase gradually to 2-3 g/kg/day; dextrose initial 4-6 mg/kg/min, titrate up to 12-15 mg/kg/min; continuous infusion via central vein.
Intravenous infusion of 1-2 g amino acids/kg/day (equivalent to 28.6-57.1 m L/kg/day of 3.5% solution). For preterm infants: start at 1 g/kg/day and advance by 0.5 g/kg/day to target 2-3 g/kg/day. Titrate based on serum amino acid profiles and growth parameters.
Start at lower end of dose range (0.5-1 g amino acids/kg/day); monitor fluid and electrolyte balance closely; adjust for renal function and comorbidities; rate reduction may be needed due to decreased metabolic reserve.
No specific dose adjustment based on age alone; however, elderly patients often have reduced renal function and lean body mass. Initiate at lower end of dosing range (e.g., 0.5 g amino acids/kg/day) and titrate slowly, monitoring renal function and fluid status.
None (not FDA-approved, but similar parenteral nutrition products carry warnings for metabolic complications, including hyperglycemia, hyperosmolar coma, and electrolyte imbalances; use in patients with severe renal or hepatic disease may require dose adjustments).
None
Risk of hyperglycemia, hyperosmolar hyperglycemic state, and rebound hypoglycemia if infusion is stopped abruptly,Monitor serum electrolytes, blood urea nitrogen (BUN), glucose, and liver function tests regularly,Use with caution in patients with renal insufficiency (may require protein restriction), hepatic failure, or metabolic disorders (e.g., maple syrup urine disease),Potential for infection and thrombophlebitis with central venous access,Do not administer if solution is discolored or contains particulate matter
Risk of metabolic acidosis,Hepatic and renal impairment may require dose adjustment,Monitor serum electrolytes, fluid balance, and ammonia levels,Do not administer if solution is cloudy or contains particulates
Known hypersensitivity to any component,Severe hyperglycemia or hyperosmolar state,Uncontrolled metabolic acidosis,Anuria or severe renal impairment (unless dialyzed),Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic insufficiency with encephalopathy
Hypersensitivity to any component,Inborn errors of amino acid metabolism,Severe hepatic failure or hepatic coma,Severe azotemia or uremia not related to dialysis
None; parenteral nutrition bypasses the gastrointestinal tract. However, monitor blood glucose if patient is on oral hypoglycemics or insulin.
No direct food interactions, as this is administered intravenously. However, concurrent oral intake should be avoided until parenteral nutrition is adjusted. Monitor for refeeding syndrome if transitioning to oral nutrition.
Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose may cause fetal hyperinsulinemia and hypoglycemia if maternal glucose levels are high. Use only if clearly needed.
Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose risks. During pregnancy, use only if clearly needed due to the risk of electrolyte imbalances, fluid overload, or metabolic disturbances that could affect the fetus. There are no adequate studies in pregnant women. The potential for fetal harm based on animal reproduction studies is not available.
Not excreted into milk in significant amounts; ingredients are normal nutrients. Compatible with breastfeeding. M/P ratio not applicable.
It is not known whether amino acids from Aminosyn 3.5% are excreted in human breast milk. The M/P ratio is not established. Caution should be exercised when administered to a nursing woman, as the effect on the breastfed infant is unknown. Consider the benefits of breastfeeding and the mother's need for the drug.
No standard dose adjustment. Monitor glucose levels closely; insulin requirements may increase due to dextrose load. Adjust infusion rate based on metabolic tolerance.
Dosing adjustments may be necessary due to increased plasma volume and altered protein metabolism in pregnancy. Increased requirements for certain amino acids (e.g., threonine, lysine) may need to be considered. Monitor nitrogen balance and adjust total amino acid dose based on maternal weight, gestational age, and clinical response. Close monitoring of plasma amino acid levels and metabolic parameters is recommended to avoid excess or deficiency.
This is a hypertonic solution (4.25% amino acids + 25% dextrose) used for peripheral parenteral nutrition; monitor for phlebitis due to high osmolality (>1000 m Osm/L); requires central venous access for long-term use; check serum electrolytes, glucose, and renal function daily; avoid abrupt discontinuation to prevent rebound hypoglycemia; contraindicated in patients with severe hyperglycemia, azotemia, or lipid metabolism disorders.
AMINOSYN 3.5% is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, blood urea nitrogen (BUN), and ammonia levels. Do not administer simultaneously with blood products via same infusion line due to risk of incompatibility. Use with caution in patients with hepatic or renal impairment. Central line administration is required for concentrations >5%, but 3.5% can be infused via peripheral vein if adequately diluted and with careful monitoring for thrombophlebitis.
This solution is given through a vein to provide nutrition when you cannot eat normally.,Report any pain, redness, or swelling at the infusion site immediately.,You may need regular blood tests to monitor your blood sugar, kidney function, and electrolytes.,Do not stop the infusion suddenly without medical advice, as this may cause low blood sugar.,Inform your healthcare provider if you have diabetes, kidney disease, or any allergies.
This medication is given intravenously to provide protein when you cannot eat normally.,You may require regular blood tests to monitor kidney and liver function, as well as electrolyte levels.,Report any signs of infection at the IV site, such as redness, swelling, or warmth.,Do not stop or adjust the infusion rate without your healthcare provider's guidance.,Inform your doctor if you have diabetes, liver disease, or kidney disease.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN 3.5%, answered by our medical review team.
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.. AMINOSYN 3.5% is a Parenteral Nutrition Solution that works by Aminosyn 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, thereby promoting nitrogen balance and tissue repair.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER and AMINOSYN 3.5% depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is: Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.. The standard adult dose of AMINOSYN 3.5% is: Intravenous administration of 500 m L to 1000 m L per day as a 3.5% amino acid solution, typically infused at a rate of 1.25-2.5 m L/min (equivalent to 0.25-0.5 g amino acids/kg/day). Dose individualized based on nitrogen requirements and metabolic status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER and AMINOSYN 3.5% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is classified as Category C. Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose m. AMINOSYN 3.5% is classified as Category C. Aminosyn 3.5% is an amino acid solution used for parenteral nutrition. No specific teratogenic risk has been established in human pregnancy; however, maternal malnutrition may pose. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.